Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of Iron Oligosaccharide in CHF Patients with Iron Deficiency Anaemia
NCT00537186Phase 3Completed
- Sponsor
- Pharmacosmos
- Start
- Jun 2007
- Primary completion
- Jul 2008
- Modality
- Inorganic Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of ferric derisomaltose in iron deficiency anemia (IDA), sponsored by Pharmacosmos. Primary endpoints: Adverse events (AE) at 8 weeks, Serious adverse events (SAEs) at 8 weeks and 3 more. Started Jun 2007; status: completed.
02
Drugs
ferric derisomaltose
03
Conditions
iron deficiency anemia (IDA)
Beyond the preview
Go deeper on NCT00537186.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00537186.